TerminatedPhase 4

Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO

Stopped: undefined

Mexico10 participantsStarted 2007-06

Plain-language summary

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Macular edema secondary to central retinal vein occlusion * BCVA worse than 20/40 * Central macular \>250 mc with OCT Exclusion Criteria: * Diabetic retinopathy or other retinopathy * Media opacity that does not allow following * steroid responder * diagnosed glaucoma or IOP \> 21 mmHg

What they're measuring

Changes in Best corrected visual acuity and macular edema measured with OCT

Timeframe: Follow up to 3 , 6 and 12 months

Trial details

NCT IDNCT00566761

SponsorAsociación para Evitar la Ceguera en México

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2007-06

View on ClinicalTrials.gov More Macular Edema trials